Additional Information | Index 2012 performance summary 24 Intangible assets 92, 97, 101, 159 Accounting policies 146, 194 Intellectual Property 35 Acquisitions and disposals 173 Interest-bearing loans and borrowings 164 Amgen 31, 55, 68, 93 Inventories 148, 163 Amylin 31, 55, 71, 93, 161 Ironwood 31, 57 Annual general meeting 121, 208 Key performance indicators 26 Ardea 31, 69, 90, 173 Leases 148, 190 Articles of association 206, 208 Lifecycle of a medicine 14 Astra Tech 174 Litigation 102, 149, 184 Audit Committee 75, 115 Market denitions 209 Biologics 17, 19, 30 Medicines 2, 14, 30, 50 Board 106, 110 Neuroscience 61 Branches 120 Nomination and Business background Governance Committee 117 and results overview 86 Oncology 65 Capitalisation 94 Operating profit 2, 4, 89, 151 Cardiovascular 52 Operational overview 4 Cash and cash equivalents 148, 164 Other investments 148, 163 Chairmans Statement 6 Patents see Intellectual Property Chief Executive Ofcers Review 8 Patient safety 34 Clinical Trials 33, 34 People 5, 24, 28, 43, 179 Code of Conduct 47 Pharmaceutical industry 16 Commitments and contingent liabilities 183 Pipeline 4, 24, 26, 30, 51, 199 Community Investment 49 Political donations 120 Company history 203, 208 Portfolio Investment Board 119 Competition 16, 78 Post-retirement benets 102, 131, 167 Compliance and Group Internal Audit 47, 75, 115 Pricing 18, 38 Consolidated statement Principal risks and uncertainties 75 of Cash Flows 145 Product revenue information 150 Consolidated statement Property, plant and equipment 148, 157 of Changes in Equity 144 Provisions for liabilities and charges 167 Consolidated statement Regulatory requirements 17 of Comprehensive Income 142 Related party transactions 190, 205 Consolidated statement Relations with shareholders 114 of Financial Position 143 Remuneration Committee 117 Corporate governance 104 Research and Development 30, 147, 151 Diabetes 52, 54 Reserves 171 Directors interest in shares 134 Respiratory & Inammation 67 Directors remuneration 122 Responsible Business 28, 48 Directors responsibility statement 140 Restructuring 21, 151 Diversity 43, 44 Results of operations 2011 95 Dividends 7, 94, 173, 205 Results of operations 2012 89 Earnings per ordinary share 5, 154 Revised Core financial measures 97 Emerging Markets 13, 73, 77, 209 Safety, health and wellbeing 46 Employee costs and share Sales and Marketing 37 plans for employees 179 Sales by geographical area 70 Established Markets 38, 72, 209 Sales by Therapy Area 50 Ethics 33, 39, 47 Science Committee 118 Finance income and expense 152 Segment information 155 Financial instruments 148, 166 Senior Executive Team 108, 118 Financial position 2011 97 Share capital 172, 196, 203 Financial position 2012 92 Share repurchase 7, 94, 173, 196 Financial risk management 99, 175 Statutory and other information 190 Financial summary 2 Strategy 20 Gastrointestinal 56 Subsidiaries 191 Glossary 209 Supply and Manufacturing 40 Goodwill 92, 97, 101, 147, 158 Taxation 99, 103, 147, 152, 189, 194 Group Financial Record 198 Taxation information for shareholders 206 Group Financial Statements 140 Trade and other payables 148, 166 Growth drivers 16 Trade and other receivables 148, 164 Human Rights 45 Trade marks 211 Independent auditors report 141, 192 Transactions with directors 133 Infection 58 World pharmaceutical markets 16 Inammation see Respiratory & Inammation 212 AstraZeneca Annual Report and Form 20-F Information 2012 Important information for readers of this Annual Report Cautionary statement regarding forward-looking statements The purpose of this Annual Report is to provide information to the members of the Company.
The Company and its Directors, employees, agents and advisers do not accept or assume responsibility to any other person to whom this Annual Report is shown or into whose hands it may come and any such responsibility or liability is expressly disclaimed.
In order, among other things, to utilise the safe harbour provisions of the US Private Securities Litigation Reform Act of 1995 and the UK Companies Act 2006, we are providing the following cautionary statement: This Annual Report contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group.
Forward-looking statements are statements relating to the future which are based on information available at the time such statements are made, including information relating to risks and uncertainties.
Although we believe that the forward-looking statements in this Annual Report are based on reasonable assumptions, the matters discussed in the forward-looking statements may be inuenced by factors that could cause actual outcomes and results to be materially different from those expressed or implied by these statements.
The forward-looking statements reect knowledge and information available at the date of the preparation of this Annual Report and the Company undertakes no obligation to update these forward-looking statements.
We identify the forward-looking statements by using the words anticipates, believes, expects, intends and similar expressions in such statements.
Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond our control, include, among other things, those factors identied in the Principal risks and uncertainties section from page 75 of this Annual Report.
Nothing in this Annual Report should be construed as a profit forecast.
Inclusion of Reported performance, Core financial measures and constant exchange rate growth rates AstraZenecas determination of non-GAAP measures together with our presentation of them within our financial information may differ from similarly titled non-GAAP measures of other companies.
Statements of competitive position, growth rates and sales In this Annual Report, except as otherwise stated, market information regarding the position of our business or products relative to its or their competition is based upon published statistical sales data for the 12 months ended 30 September 2012 obtained from IMS Health, a leading supplier of statistical data to the pharmaceutical industry.
For the US, dispensed new or total prescription data and audited sales data are taken, respectively, from IMS Health National Prescription Audit and IMS National Sales Perspectives for the 12 months ended 31 December 2012: such data is not adjusted for Medicaid and similar rebates.
Except as otherwise stated, these market share and industry data from IMS Health have been derived by comparing our sales revenue to competitors and total market sales revenues for that period.
Except as otherwise stated, growth Designed and produced by rates are given at CER.
For the purposes of this Annual Board and SET photography Marcus Lyon Report, unless otherwise stated, references to the world pharmaceutical market or similar phrases are to the This Annual Report is printed on 54 countries contained in the IMS Health MIDAS Heaven 42 which is FSC certied Quantum database, which amounted to approximately virgin bre.
The pulp is a mix, partly 92% in value of the countries audited by IMS Health.
bleached using an Elemental Chlorine Free ECF process and AstraZeneca websites partly bleached using a Totally Information on or accessible through our websites, Chlorine Free process.
com in the UK by Pureprint using and medimmune.
com, does not form part of and is not its alcofree and pureprint incorporated into this Annual Report.
environmental printing technology, External third party websites and vegetable inks were used Information on or accessible through any third party throughout.
Both the manufacturing mill and the printer are or external website does not form part of and is registered to the Environmental Management System not incorporated into this Annual Report.
ISO14001 and are Forest Stewardship Council Figures chain-of-custody certied.
Figures in parentheses in tables and in the Financial Statements are used to represent negative numbers.
Registered ofce and Investor relations Registrar US Depositary corporate headquarters ir@astrazeneca.
com Equiniti Limited JPMorgan Chase & Co AstraZeneca PLC Aspect House PO Box 64504 2 Kingdom Street UK: as above Spencer Road St Paul London W2 6BD Lancing MN 55164-0504 UK US West Sussex BN99 6DA US Tel: 44 0 20 7604 8000 Investor Relations UK Tel: toll free in the US Fax: 44 0 20 7604 8151 AstraZeneca Pharmaceuticals LP Tel: freephone in the UK 888 697 8018 1800 Concord Pike 0800 389 1580 Tel: outside the US PO Box 15437 Tel: outside the UK 1 651 453 2128 Wilmington 44 0 121 415 7033 jpmorgan.
com fide 19850-5437 US Swedish Central Securities Tel: 1 302 886 3000 Depository Fax: 1 302 886 2972 Euroclear Sweden AB PO Box 191 SE-101 23 Stockholm Sweden Tel: 46 0 8 402 9000 This Annual Report is also available on our website, astrazeneca.
